false
0001509261
0001509261
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 13, 2026
REZOLUTE, INC.
(Exact Name of Registrant as Specified in Charter)
| Nevada |
|
001-39683 |
|
27-3440894 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
275 Shoreline Drive, Suite 500, Redwood
City, CA 94065
(Address of Principal Executive Offices,
and Zip Code)
650-206-4507
Registrant’s Telephone Number, Including
Area Code
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, par value $0.001
per share |
RZLT |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry into a Material Definitive Agreement.
Underwriting Agreement
On November 13, 2026, Rezolute, Inc. (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim
Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (the “Underwriters”),
relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of (i) 22,040,976 shares
(the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”),
at an offering price of $3.8700 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up
to 3,800,000 shares of Common Stock at an offering price of $3.8690 per Pre-Funded Warrant, which represents the per share offering price
for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant.
The Shares and Pre-Funded Warrants in the Offering
are being offered pursuant to a registration statement on Form S-3 (File No. 333-299867) (the “Registration Statement”),
which was declared effective by the Securities and Exchange Commission (the “SEC”) on November 10, 2026 under the
Securities Act of 1933, as amended (the “Securities Act”).
The closing of the Offering is expected to occur
on or about November 16, 2026, subject to satisfaction of customary closing conditions. The estimated net proceeds of the Offering to
the Company, after deducting the underwriting discounts and commissions and offering expenses payable by the Company, are approximately
$93.5 million. The Company intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to fund
ersodetug commercialization preparation and for working capital and general corporate purposes.
The Underwriting Agreement contains customary
representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company
and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties and termination provisions.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and
as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the
contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution
of the Underwriting Agreement.
Subject to certain exceptions, the Company’s
executive officers and directors have agreed not to sell or otherwise dispose of any of the shares of Common Stock held by them for a
period beginning on the date of execution of the applicable lock-up agreements by each such executive officer and director and ending
30 days after the date of the final prospectus supplement filed with the SEC in connection with the Offering pursuant to Rule 424(b) under
the Securities Act without first obtaining the written consent of Morgan Stanley.
The Pre-Funded Warrants offered in the Offering
have an exercise price of $0.001 per share, which is subject to adjustment in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the shares of Common Stock and also upon any distributions
for no consideration of assets to the Company's stockholders. Each Pre-Funded Warrant is exercisable at any time and from time to time
after issuance. In the event of certain fundamental transactions, the holders of the Pre-Funded Warrants will be entitled to receive,
upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that the holders would have received
had they exercised the Pre-Funded Warrants immediately prior to such transaction. The Pre-Funded Warrants do not entitle the holders
thereof to any voting rights or any of the other rights or privileges to which holders of Common Stock are entitled. The Company may
not effect the exercise of any Pre-Funded Warrants, and a holder will not be entitled to exercise any portion of any Pre-Funded Warrant
that, upon giving effect to such exercise, would result in: (i) the aggregate number of shares of Common Stock beneficially owned by
such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares
of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s
securities beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, up to
19.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants, which percentage may be
changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to
the Company. The foregoing summary of the Pre-Funded Warrants does not purport to be complete and is subject to, and qualified in its
entirety by, the form of Pre-Funded Warrant, which is filed herewith as Exhibit 4.1 and incorporated herein by reference.
The foregoing summary of the Underwriting Agreement
does not purport to be complete and is subject to, and qualified in its entirety by, the Underwriting Agreement, which is filed herewith
as Exhibit 1.1 and incorporated herein by reference.
A copy of the opinion of Dorsey & Whitney
LLP relating to the legality of the issuance and sale of the Shares and the Pre-Funded Warrants offered in the Offering, and shares of
Common Stock issuable upon the exercise of the Pre-Funded Warrants offered in the Offering, is attached as Exhibit 5.1 hereto and is
incorporated by reference herein.
Item 7.01. Regulation FD Disclosure.
Pricing Press Release
On November 13, 2026, the Company issued a
press release announcing the pricing of the Offering. A copy of the press release is attached hereto as Exhibit 99.1.
The information in Item 7.01 of this Current
Report on Form 8-K, including the attached Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed”
for any purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of such Section, and shall not be deemed to be incorporated by reference into any of the Company's filings
under the Securities Act or the Exchange Act, whether made before or after the date hereof, and regardless of any general incorporation
language in such filings, except to the extent expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
| 1.1 |
Underwriting Agreement, dated as of November 13, 2026, by and between the Company and Morgan
Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named
therein |
| 4.1 |
Form of Pre-Funded Warrant |
| 5.1 |
Opinion of Dorsey & Whitney LLP |
| 23.1 |
Consent of Dorsey & Whitney LLP (included in Exhibit 5.1) |
| 99.1* |
Press Release, dated November 13, 2026 |
| 104 |
Cover Page Interactive Data File (formatted as inline XBRL) |
* This exhibit is intended to be furnished to, not filed
with, the SEC pursuant to Regulation FD.
Caution Concerning Forward-Looking Statements
This Current Report on Form 8-K may contain forward-looking
statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act,
as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified
by the use of words such as “may,” “will,” “expect,” “project,” “estimate,”
“anticipate,” “plan,” “believe,” “potential,” “should,” “continue”
or the negative versions of those words or other comparable words. These forward-looking statements include statements about the closing
of the Offering and the anticipated use of proceeds of the Offering. These forward-looking statements are based on information currently
available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly
affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as
a result of many factors, including the uncertainties related to market conditions, the satisfaction of customary closing conditions
related to the Offering, and the completion of the Offering on the anticipated terms or at all. The Company’s forward-looking statements
also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied
by such forward-looking statements. These and other risks concerning the Company’s business are described in additional detail
in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2026, in the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2026 and in the Company’s other reports filed with the SEC. The Company is under
no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
REZOLUTE, INC. |
| |
|
|
| DATE: November 16, 2026 |
By: |
/s/ Nevan Charles Elam |
| |
|
Nevan Charles Elam |
| |
|
Chief Executive Officer |
Exhibit 99.1
Rezolute Announces Pricing of Approximately
$100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Transaction led by Frazier Life
Sciences with participation from new and existing funds
REDWOOD CITY, Calif., November 13, 2026 –
Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory
hypoglycemia caused by any form of hyperinsulinism (HI), today announced the pricing of an underwritten offering of 22,040,976 shares
of its common stock at an offering price of $3.87 per share, and to certain investors in lieu of common stock, pre-funded warrants to
purchase up to 3,800,000 shares of common stock at an offering price of $3.869 per pre-funded warrant, which represents the per share
offering price for the common stock, less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to
Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately
$100 million. The offering is expected to close on or about November 16, 2026, subject to the satisfaction of customary closing conditions.
The Company intends
to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization
preparation, working capital and general corporate purposes.
The financing is being led by Frazier Life Sciences
and includes participation from new and existing funds.
Morgan Stanley, Guggenheim Securities, and Cantor
are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Jones are acting as lead managers for the offering.
Maxim Group LLC and Lake Street Capital Markets, LLC are acting as co-managers for the offering.
The securities in the registered offering are
being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-299867), filed with the U.S.
Securities and Exchange Commission (the “SEC”) on November 5, 2026, and declared effective on November 10, 2026. A prospectus
supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available
on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering, when available,
may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com; Guggenheim Securities, LLC, Attention: Equity
Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, or by phone: 1-212-518-9544, or by email: GSEquityProspectusDelivery@guggenheimsecurities.com;
or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 East 59th Street, 6th Floor, New York, New
York 10022, or by email: prospectus@cantor.com.
This press release
shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.
About Rezolute,
Inc.
Rezolute is a late-stage ultra-rare,
metabolic disease company focused on treating refractory hypoglycemia
caused by any form
of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug,
has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due
to a variety of causes of HI.
Forward-Looking
Statements
This
release, like many written and oral communications presented by Rezolute and its authorized officers, may contain
certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities
Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including
this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe
future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe,"
"estimate," "expect," "intend," "plan," "project," "seek," "strive,"
"try," or future or conditional verbs such as "could," "may," "should," "will," "would,"
or similar expressions. These forward-looking statements include, but are not limited to, Rezolute’s expectations regarding the
anticipated use of proceeds and the completion of the offering. The Company’s ability to predict results or the actual effects
of its plans or strategies is inherently uncertain. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation
to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were
made. Important factors that may cause such a difference include, among others, those related to market and other financial conditions,
satisfaction of customary closing conditions related to the offering, and any other factors discussed in Rezolute’s filings with
the SEC, including the Risk Factors contained in Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which
are available at the U.S. Securities and Exchange Commission’s website at www.sec.gov. You are urged to consider these factors
carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by this cautionary statement.
Rezolute Contacts:
Christen Baglaneas
Rezolute, Inc.
1411 Broadway,
16th Floor
New York, NY 10018
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
Rezolute, Inc.
1411 Broadway,
16th Floor
New York, NY 10018
cmckim@rezolutebio.com
336-608-9706